Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 10-Q Report Quarterly Report
  2. 8-K Event Results of operations
  3. 10-K/A Report 10-K/A
  4. 3 Insider Initial Statement of Ownership
  5. DEF 14A Proxy Proxy Statement
  6. 8-K Event Executive or director change
  7. 4 Option exercise EVP, Chief Financial Officer acquired 8,000 shares (option exercise)
  8. 4 Grant or award Director acquired 410 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. SC 13D/A Stake Beneficial Ownership Report
  11. 4 Open-market sale Director sold 39,245 shares at an average $23.87 ($936,743)
  12. 10-K Report Annual Report
  13. 8-K Event Results of operations
  14. SC 13D/A Stake Beneficial Ownership Report
  15. SC 13G/A Stake Amended Statement of Ownership
  16. SC 13G/A Stake Amended Statement of Ownership
  17. SC 13G/A Stake Amended Statement of Ownership
  18. 4 Open-market sale 10% owner sold 550,645 shares at $26.78 ($14,746,273)
  19. SC 13D/A Stake Beneficial Ownership Report
  20. 4 Derivatives Options or other derivatives

Page 29 of 37 · 725 filings